Role of Cell-Based Therapies in T2D

Sudipta Ashe; Matthias Hebrok

doi:10.1016/j.semnephrol.2023.151432

Role of Cell-Based Therapies in T2D

Semin Nephrol. 2023 May;43(3):151432. doi: 10.1016/j.semnephrol.2023.151432. Epub 2023 Oct 31.

Authors

Sudipta Ashe¹, Matthias Hebrok²

Affiliations

¹ Diabetes Center, Department of Medicine, University of California, San Francisco, CA.
² Diabetes Center, Department of Medicine, University of California, San Francisco, CA; TUM School of Medicine, Technical University Munich, Munich, Germany; Center for Organoid Systems, Technical University Munich, Garching, Germany; Institute for Diabetes and Organoid Technology, Helmholtz Diabetes Center, Helmholtz Zentrum München, Neuherberg, Germany; Munich Institute of Biomedical Engineering (MIBE), Technical University Munich, Munich, Germany; German Center for Diabetes Research (DZD), Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany. Electronic address: matthias.hebrok@tum.de.

PMID: 37918206
DOI: 10.1016/j.semnephrol.2023.151432

Abstract

Type 2 diabetes mellitus (T2D) has become a global epidemic affecting the health of millions of people. T2D is a complex and multifactorial metabolic disease, largely characterized by a combination of impaired insulin secretion from β cells residing within the islets of the pancreas and peripheral insulin resistance. In this article, we discuss the current state and risk factors for T2D, conventional treatment options, and upcoming strategies, including progress in the areas of allogeneic and xenogeneic islet transplantation, with a major focus on stem cell-derived β cells and associated technologies.

Keywords: T(reg) therapy; Type 2 diabetes mellitus; clinical trials; immune modulation; stem cell therapy; β cells.

Publication types

Review

MeSH terms

Diabetes Mellitus, Type 2* / metabolism
Diabetes Mellitus, Type 2* / therapy
Humans
Insulin / metabolism
Insulin / therapeutic use
Insulin Resistance*
Insulin Secretion

Substances

Insulin